Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Apr:105:722.
doi: 10.1016/j.ijid.2021.02.035. Epub 2021 Feb 15.

Letter to the editor on "Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial" by Udwadia et al

Mahender Kumar Medisetty  1 , Atul Patel  2 , Sanjay Pujari  3
Affiliations
Comment

Letter to the editor on "Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial" by Udwadia et al

Mahender Kumar Medisetty et al. Int J Infect Dis. 2021 Apr.
No abstract available

PubMed Disclaimer

Comment in

Comment on

References

    1. COVID-19 Treatment Guidelines Panel . National Institutes of Health; 2021. Coronavirus disease 2019 (COVID-19) treatment guidelines. Available at https://www.covid19treatmentguidelines.nih.gov/. [Accessed 11 December 2020] - PubMed
    1. McCoy C.E. Understanding the intention-to-treat principle in randomized controlled trials. West J Emerg Med. 2017;18(6):1075–1078. - PMC - PubMed
    1. Moye L.A. End-point interpretation in clinical trials: the case for discipline. Control Clin Trials. 1999;20(1):40–49. discussion 50–51. - PubMed
    1. Rockhold Frank, Segreti Tony. Methods and applications of statistics in clinical trials. 2014. Secondary efficacy end points; pp. 731–739. 2.
    1. Spinner C.D., Gottlieb R.L., Criner G.J., Arribas Lopez J.R., Cattelan A.M., Soriano Viladomiu A. Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial. JAMA. 2020;324(11):1048–1057. - PMC - PubMed